> Strong growth from Merck KGaA's multiple sclerosis drug Rebif and cancer treatment Erbitux helped push the German drugmakers second-quarter sales past expectations as 376 million euros' worth of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback